سعر بارسيميانت 4 مجم28 قرص 2026

Baricitinib 4 mg tablets by EVA Pharma (Egypt), listed by Egyptian price directories as film-coated tablets, 28 per pack (4 strips); an oral Janus kinase (JAK1/JAK2) inhibitor. The manufacturer portfolio lists it for rheumatoid arthritis in adults not well controlled by TNF inhibitors.

• Rheumatoid arthritis in adults whose disease was not well controlled by tumor necrosis factor inhibitorsPopulation: AdultsEVA Pharma (manufacturer)
• Moderate to severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more DMARDs (monotherapy or with methotrexate)Population: AdultsEuropean Medicines Agency (EMA)
• Moderate to severe atopic dermatitis in patients who are candidates for systemic therapyPopulation: Adults and children aged 2 years and olderEuropean Medicines Agency (EMA)

• Most common: increased LDL cholesterol (26.0%), upper respiratory tract infections (16.9%), headache (5.2%), herpes simplex (3.2%) and urinary tract infections (2.9%). Other listed reactions include herpes zoster, pneumonia, gastroenteritis, thrombocytosis, nausea, abdominal pain, ALT increase, rash and acne; uncommon: neutropenia, deep vein thrombosis, pulmonary embolism, diverticulitis.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to baricitinib or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)
• Pregnancy.International label, same formulation · European Medicines Agency (EMA)

• Use only if no suitable treatment alternatives are available in patients aged 65 or older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), and patients with malignancy risk factors (increased MACE, malignancy, serious infections and all-cause mortality were seen with another JAK inhibitor, tofacitinib).International label, same formulation · European Medicines Agency (EMA)
• Infections: increased rate of infections such as upper respiratory tract infections; consider risks before starting in active, chronic or recurrent infection and interrupt if an infection does not respond to standard therapy. Screen for tuberculosis before starting; do not give to patients with active TB. Screen for viral hepatitis; herpes zoster reactivation has been reported (interrupt until resolved).International label, same formulation · European Medicines Agency (EMA)
• Haematological abnormalities: do not initiate, or temporarily interrupt, if absolute neutrophil count <1 x 10^9 cells/L, absolute lymphocyte count <0.5 x 10^9 cells/L or haemoglobin <8 g/dL.International label, same formulation · European Medicines Agency (EMA)

• Strong OAT3 inhibitors (e.g., probenecid)Probenecid roughly doubled baricitinib AUC; recommended adult dose is 2 mg once daily (halve the paediatric dose).European Medicines Agency (EMA)
• Leflunomide / teriflunomideTeriflunomide is a weak OAT3 inhibitor and may increase baricitinib exposure; use with caution.European Medicines Agency (EMA)
• Biological DMARDs, biological immunomodulators, other JAK inhibitors; potent immunosuppressants (e.g., azathioprine, tacrolimus, ciclosporin)Combination with biologics or other JAK inhibitors is not recommended (additive immunosuppression cannot be excluded); limited data with potent immunosuppressants in RA/JIA (caution), not recommended in atopic dermatitis and alopecia areata.European Medicines Agency (EMA)

• Contraindicated during pregnancy: the JAK/STAT pathway is involved in early embryonic development, there are no adequate human data, and baricitinib was teratogenic in rats and rabbits. Women of childbearing potential must use effective contraception during and for at least 1 week after treatment.International label, same formulation · European Medicines Agency (EMA)
• Based on animal reproduction studies, OLUMIANT may cause fetal harm; available human data are insufficient to inform a drug-associated risk. Consider the risks and benefits of chronic use during pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Should not be used during breast-feeding; baricitinib is excreted in animal milk and a risk to the infant cannot be excluded.International label, same formulation · European Medicines Agency (EMA)

• Baricitinib: Selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2, which transduce intracellular signals for cytokines and growth factors involved in haematopoiesis, inflammation and immune function (EU SmPC).